Lesion count
DrugLesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Other names: AK lesion recurrence
NCT Number: NCT00952783
This study is designed to follow up patients, who have achieved complete clearance of AK lesions (lesion count of 0) at Day 57 in the PEP005-020 study, over a 12 month period to assess both recurrence of Actinic Keratosis (AK) lesions and long term safety in the selected treatment area.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Dematology on Ward, Adelaide, South Australia, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion
Exclusion
Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
Other names: AK lesion recurrence
Time frame: 12 months
Time frame: 12 months
Peplin
Industry
A 12 Month, Long-term Follow-up Study of Patients With Actinic Keratosis on Non-head Areas (Trunk and Extremities) Who Have Completed Day 57 in Study PEP005-020
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06888362
Actinic Keratosis, Keratosis
Uppsala, Sweden
View Trial DetailsNCT06027619
Actinic Keratosis, Keratosis
Cleveland, Ohio, United States
View Trial DetailsNCT06319794
Actinic Keratosis, Keratosis
Basel, Switzerland
View Trial DetailsNCT00472459
Actinic Keratosis, Basal Cell Carcinoma
Aarhus, Denmark
View Trial Details